

MODERN PERSPECTIVES ON THE ETIOPATHOGENESIS OF MENINGOCOCCAL INFECTION

<https://doi.org/10.5281/zenodo.19999355>

¹Rakhmatullaeva Shakhnoza Bakhadirovna, ²Sadullayev Siroj Ernazarovich,
³Matkarimov Matkarim Jaloliddin o'g'li

¹Doctor of Medical Sciences Professor at the Department of Infectious Diseases and
Pediatric Infectious Diseases, Tashkent State Medical University, Tashkent, Uzbekistan,

²Assistant at the Department of Infectious Diseases, Epidemiology and Phthisiology,
Urgench State Medical Institute, Urgench, Uzbekistan,

³A 2nd-year student of the General Medicine program at the 2nd Faculty of Medicine,
Urgench State Medical Institute

E-mail: Doctor_shakhnoza@mail.ru

Orcid id: <https://orcid.org/0000-0001-7257-2081>

E-mail: sadullayev.siroje@gmail.com

Orcid id: <https://orcid.org/0009-0006-4052-7183>

Background

Meningococcal infection, caused by *Neisseria meningitidis*, remains a leading cause of bacterial meningitis and septicemia worldwide, with case fatality rates ranging from 10% to 15% even when optimal antimicrobial therapy is initiated promptly. The infection disproportionately affects children under five years and adolescents, imposing a substantial global health burden. Despite decades of research, the intricate molecular interplay between the pathogen and the host immune system continues to reveal new layers of complexity. Objective: This review synthesizes current evidence on the etiology, virulence determinants, and pathogenetic mechanisms of meningococcal disease, with emphasis on molecular and genomic advances published between 2019 and 2025. Methods: A systematic narrative review was conducted using PubMed, Scopus, and WHO databases. Studies were selected based on relevance to pathogenesis, virulence factor biology, host genetics, and emerging antibiotic resistance patterns. Key Findings: The polysaccharide capsule, type IV pili, lipooligosaccharide (LOS), and complement-evasion proteins constitute the principal virulence armamentarium of *N. meningitidis*. Crossing the blood-brain barrier involves a sequence of adhesin-receptor interactions, paracellular junction disruption, and transcytosis facilitated by outer membrane proteins. Cytokine storm, driven predominantly by LOS-mediated TLR4 signaling, underlies the severity of septic shock. Host genetic polymorphisms in complement components (C5-C9), mannose-binding lectin, and

Toll-like receptors substantially modulate individual susceptibility. Conclusion: Advances in genomics and proteomics are redefining our understanding of meningococcal pathogenesis and informing next-generation vaccine design. Critical knowledge gaps remain regarding the mechanisms of BBB crossing and the determinants of disease severity in immunocompetent individuals.

Keywords

Neisseria meningitidis; meningococcal infection; etiopathogenesis; virulence factors; lipooligosaccharide; blood-brain barrier; complement evasion; cytokine storm; host genetics; meningococcal vaccines

INTRODUCTION

Meningococcal disease occupies a unique and sobering position in the landscape of infectious diseases: it can progress from early non-specific symptoms to fulminant septic shock or death within hours, and yet the causative organism, *Neisseria meningitidis*, colonizes the nasopharynxes of approximately 10–35% of healthy adults without causing any apparent illness [1]. This paradox – a commensal that becomes a lethal pathogen – has driven intensive scientific inquiry since Weichselbaum first described the meningococcus in 1887, and it continues to generate productive research directions well into the twenty-first century.

According to the Global Burden of Disease study updated in 2023, bacterial meningitis caused by *N. meningitidis* accounts for roughly 170,000 deaths annually, with a disproportionate burden falling on sub-Saharan Africa’s so-called “meningitis belt” stretching from Senegal to Ethiopia [2]. Serogroup A epidemics historically dominated this region, but the introduction of MenAfriVac led to a dramatic epidemiological shift, with serogroups C, W, and X now accounting for an increasing proportion of cases [3]. In Europe and North America, serogroups B and C are most prevalent, and the emergence of hypervirulent clonal complexes such as ST-11 (cc11) and ST-41/44 has been associated with outbreaks characterized by high case fatality and severe sequelae.

Despite the availability of polysaccharide and conjugate vaccines against multiple serogroups and the introduction of multicomponent serogroup B vaccines (4CMenB; MenB-FHbp), meningococcal disease remains unpredictable and incompletely controlled. This is attributable, in part, to the extraordinary genetic plasticity of *N. meningitidis*, which acquires and discards genes through horizontal gene transfer, altering antigen expression and evading vaccine-induced immunity [4]. A thorough understanding of etiopathogenesis is therefore not merely an

academic exercise but a prerequisite for rational vaccine optimization, improved diagnostic algorithms, and targeted therapeutic intervention.

The present review aims to provide a critical and updated synthesis of the molecular, cellular, and immunological mechanisms underlying meningococcal pathogenesis, integrating findings from genomics, proteomics, and clinical immunology published over the past six years. By delineating both established mechanisms and areas of ongoing scientific debate, we aim to offer a framework that can inform translational research and clinical practice.

LITERATURE REVIEW

The scientific literature on *N. meningitidis* pathogenesis has expanded considerably in the years 2019–2025, driven by high-throughput sequencing technologies, CRISPR-based functional genomics, and single-cell transcriptomics. Several thematic clusters are discernible.

Advances in Understanding Adhesion and Invasion

Work by Coureuil and colleagues (2019, 2022) has refined the mechanistic understanding of pilus-mediated adhesion to human brain endothelial cells, demonstrating that type IV pili trigger Src kinase-dependent phosphorylation of ezrin and radixin, which reorganizes the cortical actin cytoskeleton to form “microvillus-like protrusions” that engulf meningococcal microcolonies [5]. This process is now understood to be far more dynamic than the classical two-step adhesion-invasion model suggested. Complementary single-molecule imaging studies have resolved the nanoscale architecture of pilus-receptor contacts, showing that each pilus fiber can exert retraction forces exceeding 100 piconewtons, contributing to mechanical distortion of tight junction proteins including ZO-1 and claudin-5 [6].

Complement Evasion: New Molecular Detail

The factor H-binding protein (fHbp) has emerged as a focal point of both basic and translational research. Structural studies published between 2020 and 2024 have delineated allelic variants within three subfamilies (previously two), with subfamily B variant 24 associated with disproportionately high invasive disease risk in Europe [7]. Critically, variants differ not only in fH binding affinity but also in their ability to bind complement protein C4b-binding protein (C4BP), which adds an additional layer of complement evasion not previously appreciated. Pajon et al. (2021) demonstrated that strains with high fHbp expression and concomitant Opc upregulation exhibit synergistic complement resistance, potentially explaining why some carriage strains transition to invasive phenotypes following respiratory viral co-infection [8].

The Role of LOS in Immunopathology

The lipooligosaccharide of *N. meningitidis* has long been recognized as the principal endotoxin mediating cytokine release, but recent work has substantially refined the molecular details. Devoe et al. (2023) used native mass spectrometry to characterize the stoichiometry of LOS-TLR4-MD-2 complex formation, demonstrating that even at picomolar concentrations, LOS hexaacylated forms saturate TLR4 signaling with greater efficiency than lipopolysaccharide from many Gram-negative enteropathogens [9]. The implication is that the exceptionally rapid cytokine release in meningococcal sepsis reflects not only bacterial load but the intrinsic potency of meningococcal endotoxin. The molecular mimicry of host gangliosides by LOS lacto-N-neotetraose extensions also contributes to evasion of innate immune surveillance, and the switch between lacto-N-neotetraose and other LOS structures is regulated by phase variation of the *lgtA* gene, which modulates immunogenicity dynamically during infection [10].

Gaps in Current Knowledge

Despite these advances, important questions remain. The trigger for transition from asymptomatic carriage to invasive disease in the vast majority of contacts who do not develop illness remains poorly defined. The relative contributions of transient defects in innate immunity (e.g., post-viral mucosal barrier disruption) versus stochastic expression of meningococcal virulence genes versus host genetic susceptibility remain contested. Furthermore, the role of the nasopharyngeal microbiome in modulating susceptibility – with mounting evidence that dysbiosis precedes invasive episodes in some individuals – has not been formally integrated into the current pathogenesis framework [11].

ETIOLOGY OF MENINGOCOCCAL INFECTION

Microbiological Characteristics of *Neisseria meningitidis*

Neisseria meningitidis is an obligately aerobic, Gram-negative diplococcus with a characteristic coffee-bean morphology on Gram stain. It is a fastidious organism, requiring enriched media (e.g., chocolate agar, Mueller-Hinton blood agar) and a 5–7% CO₂ atmosphere for optimal growth. The organism is uniquely adapted to the human nasopharynx, its exclusive ecological reservoir; no animal reservoir has been convincingly identified. The genome of *N. meningitidis* is approximately 2.2 megabase pairs, with substantial inter-strain variability – comparative genomics of the reference strains MC58, Z2491, and FAM18 reveals that roughly 25% of the genome constitutes a flexible gene pool subject to horizontal transfer [1].

The outer membrane is architecturally complex, comprising three classes of outer membrane proteins (OMPs), a distinct lipopolysaccharide-like structure termed lipooligosaccharide (lacking the O-antigen repeats of classical LPS), and several lipoproteins with immunomodulatory functions. The absence of an O-

antigen distinguishes meningococcal endotoxin from that of enteric pathogens and has important implications for its serogroup-independent immunostimulatory potency. Phase variation – the stochastic switching of gene expression through slipped-strand mispairing in homopolymeric nucleotide tracts – generates phenotypic heterogeneity within clonal populations, conferring selective advantage in the face of fluctuating host immune environments [4].

Serogroups and Clinical Relevance

Classification of *N. meningitidis* into 13 serologically defined serogroups (A, B, C, E, H, I, K, L, W, X, Y, Z, and 29E) is based on the antigenic and chemical composition of the polysaccharide capsule. Of these, six – A, B, C, W, X, and Y – account for virtually all invasive disease globally. Serogroup distribution exhibits marked geographic and temporal variation. Serogroup A was responsible for large-scale epidemic meningitis in sub-Saharan Africa and parts of Asia throughout the twentieth century, but its prevalence has been dramatically curtailed by conjugate vaccination; in the African meningitis belt, serogroup A accounted for only 1% of confirmed meningococcal cases by 2019–2022 [3].

Serogroup B presents the most formidable vaccination challenge, as its capsular polysaccharide (α -2,8-linked polysialic acid) is structurally identical to the neural cell adhesion molecule (NCAM) expressed on fetal brain tissue, rendering it poorly immunogenic and raising theoretical autoimmune concerns if used as a vaccine antigen. Multicomponent protein-based vaccines (4CMenB/Bexsero; MenB-FHbp/Trumenba) circumvent this limitation by targeting conserved outer membrane proteins, achieving modest but clinically meaningful protection [12]. Serogroup W, historically causing predominantly mild disease, has undergone a striking phenotypic shift since the emergence of a hypervirulent cc11 clone around 2000; cases caused by this strain are characterized by atypical gastrointestinal presentations, higher case fatality, and a predilection for adolescents and the elderly [13].

Transmission Mechanisms

Transmission of *N. meningitidis* occurs via direct contact with respiratory secretions from colonized individuals; the organism is susceptible to desiccation and does not survive outside the human host for more than a few seconds under ambient conditions. Risk factors for acquisition include close or prolonged contact with a carrier (household, dormitory, military barracks), active or passive exposure to cigarette smoke (which impairs mucociliary clearance and epithelial barrier integrity), and antecedent upper respiratory viral infection. The epidemiology of carriage is distinct from that of disease: carriage prevalence peaks in adolescents and young adults (20–35%), yet invasive disease peaks in infants and children

under two years, pointing to the central protective role of maternally acquired antibody and innate immune maturation [1, 2].

PATHOGENESIS (CORE SECTION)

Nasopharyngeal Colonization

The pathogenesis of invasive meningococcal disease begins, in every case, with colonization of the nasopharyngeal epithelium. This is a multi-step process that is exquisitely dependent on the expression and functional integrity of meningococcal adhesins. Type IV pili (Tfp), encoded principally by the *pilE* gene, mediate the initial reversible attachment to non-ciliated columnar epithelial cells by binding to human CD147 (EMMPRIN/Basigin) and, more recently characterized, to carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) [5]. This initial pilus-mediated attachment is followed by retraction of the pili, drawing the bacterium into close membrane-to-membrane contact with the host cell surface.

At this stage, a second adhesin, Opa (opacity protein), engages CEACAM receptors on epithelial cells via its hypervariable loops, while the autotransporter protein NadA (meningococcal adhesin A) binds β -1 integrin and facilitates intracellular entry. Crucially, the simultaneous engagement of multiple adhesin-receptor pairs creates what has been termed “multivalent adhesion”, a thermodynamically favorable configuration that resists mechanical dislodgement by mucociliary flow. The nasopharyngeal environment imposes substantial selective pressure: antimicrobial peptides (defensins, cathelicidin), secretory IgA, and lactoferrin all constitute mucosal immune barriers that meningococci counteract through specific molecular mechanisms, including IgA1 protease secretion, lactoferrin-binding proteins (LbpAB) that scavenge iron, and modification of lipid A to reduce cationic antimicrobial peptide binding [10].

Epithelial Barrier Crossing and Subepithelial Invasion

Following stable colonization, a minority of strains – presumably through stochastic upregulation of invasion genes, environmental cues, or facilitation by host barrier disruption – traverse the epithelial layer. Two primary mechanisms are recognized: transcytosis through epithelial cells (most extensively demonstrated for Opa-expressing strains binding CEACAM3 and CEACAM6) and paracellular invasion through disrupted tight junctions. The paracellular route is facilitated by meningococcal toxin-like molecules and by physical distortion of tight junction architecture mediated by pilus retraction forces acting on ZO-1 and occludin [6].

Once in the subepithelial space, *N. meningitidis* encounters the first line of phagocytic defense: tissue-resident macrophages and dendritic cells. Encapsulated strains are remarkably resistant to phagocytosis; the polysaccharide capsule sterically hinders complement receptor engagement and C3b opsonization by

preventing access of the complement membrane attack complex to the bacterial outer membrane. Studies using capsule-null mutants confirm that unencapsulated organisms are rapidly cleared by macrophages, whereas isogenic encapsulated strains persist and proliferate [4]. Non-immune serum (lacking pre-existing anti-capsular antibody) provides insufficient opsonization, which mechanistically explains the susceptibility of infants after waning of maternal IgG.

Bloodstream Dissemination

Entry into the bloodstream — meningococcemia — represents a catastrophic shift in host-pathogen dynamics. *N. meningitidis* subverts vascular homeostasis by several converging mechanisms. First, outer membrane vesicle (OMV) shedding amplifies endotoxin load far beyond what the replicating bacteria alone would contribute; patients with fulminant meningococcal sepsis have plasma LOS levels 10–50-fold higher than those with bacteremia from other Gram-negative organisms at comparable bacterial densities [9]. Second, meningococcal LOS activates the extrinsic coagulation pathway through tissue factor induction on monocytes and endothelial cells, initiating the cascade that leads to disseminated intravascular coagulation (DIC), the hallmark complication of meningococcal septicemia clinically manifest as the purpuric rash.

The complement system is the primary bactericidal defense in the bloodstream: the terminal complement complex (TCC, C5b-9) forms pores in the bacterial outer membrane and lyses encapsulated meningococci. Terminal complement deficiencies (C5-C9) increase invasive disease risk by up to 1000-fold, underscoring the non-redundant role of this pathway [2]. Factor H-binding protein (fHbp), present on all invasive *N. meningitidis* strains, counteracts complement-mediated killing by recruiting the host complement regulator factor H to the bacterial surface, thereby accelerating C3b degradation and preventing TCC assembly. Strains with higher fHbp expression consistently show greater serum resistance in bactericidal assays [7]. Additionally, the Opa protein class Opc binds serum vitronectin and clusterin, which are host TCC inhibitors, providing a second complement evasion mechanism during bacteremia [8].

Crossing the Blood-Brain Barrier

The blood-brain barrier (BBB) in the context of meningococcal disease consists principally of highly polarized brain microvascular endothelial cells (BMECs), joined by exceptionally tight junctional complexes, ensheathed by pericytes and astrocyte end-feet, and protected by an abluminal glycocalyx. *N. meningitidis* breaches this formidable barrier through a mechanism that is distinct from those of other neuroinvasive bacteria such as *Streptococcus pneumoniae* or *Listeria monocytogenes*, and which is still incompletely understood.

Current evidence supports a predominantly transcytotic route for meningococcal BBB crossing. Adhesion of *N. meningitidis* to BMECs is mediated primarily by Opc binding to fibronectin-integrin $\alpha_5\beta_1$ bridges, and by pilus-mediated engagement of CD147 on BMEC luminal surfaces. Pilus retraction generates the mechanical force necessary to invaginate BMEC apical membranes, initiating macropinocytosis-like uptake [5]. Intracellularly, meningococci reside transiently within early endosomes, resisting maturation to lysosomes through mechanisms that likely involve LOS-mediated endosomal pH buffering and interference with Rab7 recruitment. Exocytosis at the basolateral BMEC surface releases viable meningococci into the subarachnoid space.

Recent work by Coureuil's group has further demonstrated that meningococcal microcolonies on BMEC surfaces activate a Src-cortactin-Arp2/3 signaling cascade that transiently increases BMEC permeability by internalization of tight junction proteins, including ZO-1, claudin-5, and occludin [6]. This paracellular route, acting in concert with transcytosis, may explain the rapidity with which meningococci seed the cerebrospinal fluid in experimental models. In the subarachnoid space, replication is virtually unimpeded: CSF lacks the complement proteins, antibodies, and phagocytes found in serum, creating what has aptly been described as a "permissive immunological sanctuary".

Virulence Factors: An Integrated Analysis

The principal virulence determinants of *N. meningitidis* and their pathophysiological roles are summarized in Table 1. Rather than acting independently, these factors constitute an integrated armamentarium in which individual components compensate for the others' deficiencies. For example, capsule-mediated complement evasion acts in the bloodstream, while fHbp-mediated complement evasion is operative at both the mucosal surface and in blood. LOS stimulates the inflammatory cascade that, paradoxically, damages the host more than the pathogen itself. This asymmetry — where the host's immune response is the proximate cause of morbidity — is central to the clinical management challenge.

Table 1. Principal virulence factors of *Neisseria meningitidis* and their clinical significance

Virulence Factor	Primary Function	Clinical / Pathological Significance
Polysaccharide capsule	Antiphagocytic shield; prevents complement deposition	Essential for invasive disease; absent capsule is avirulent
Type IV pili (tfpB,	Adhesion to nasopharyngeal	Required for initial colonization and

pilC1/2)	epithelium; twitching motility	crossing epithelial barrier
Lipooligosaccharide (LOS)	Endotoxin; TLR4 agonist; molecular mimicry	Triggers cytokine storm; correlates with shock severity
Outer membrane proteins (PorA, PorB)	Porin function; complement evasion (PorB); antigenicity	PorB inhibits C3 deposition; targets for vaccine development
Factor H-binding protein (fHbp)	Binds host complement regulator fH; downregulates complement	Key vaccine antigen (MenB vaccines); high antigenic variation
IgA1 protease	Cleaves secretory IgA1 at hinge region	Nullifies mucosal immune defense; facilitates colonization persistence
Opc (Class 5 OMP)	Invasion via fibronectin and vitronectin bridges	Mediates transcytosis across BBB; upregulated by high-osmolarity

Source: Synthesized from references [1, 4, 5, 7, 8, 10, 12].

Host Immune Response and Cytokine Storm

The immune response to meningococcal infection is fundamentally a double-edged sword. On one side, it is the only effective mechanism for clearance of the bacterium; on the other, its uncontrolled amplification constitutes the direct mechanism of organ failure in septicemic disease. LOS released from outer membrane vesicles and from dying bacteria activates TLR4/MD-2 complexes on monocytes, macrophages, dendritic cells, and endothelial cells. This results in NF- κ B nuclear translocation and the transcriptional upregulation of a broad array of pro-inflammatory cytokines, including TNF- α , IL-1 β , IL-6, IL-8, and IL-12, as well as type I interferons [9].

TNF- α occupies a particularly central position in the pathogenesis of septic shock: it directly induces endothelial cell apoptosis, increases vascular permeability through disruption of VE-cadherin junctions, and synergizes with IL-1 β to stimulate tissue factor expression. Plasma TNF- α levels in patients with meningococcal septicemia correlate inversely with survival – a relationship that is more robust for meningococcal LOS than for LPS from enteric pathogens, consistent with the intrinsically higher TLR4-stimulating potency of hexaacylated meningococcal LOS forms [9]. The resulting cytokine storm drives systemic vasodilation, loss of plasma oncotic pressure, myocardial depression (mediated partly by TNF- α and IL-6), and ultimately multi-organ dysfunction syndrome (MODS).

Simultaneously, meningococcal products activate the complement system through all three pathways (classical, alternative, and lectin), generating C3a and

C5a anaphylatoxins that further amplify vascular permeability and recruit neutrophils. DIC ensues through the convergent effects of tissue factor induction, thrombin generation, and consumption of natural anticoagulants (protein C, antithrombin III), manifesting clinically as the purpura fulminans and digital gangrene that characterize severe meningococcal septicemia. The Waterhouse-Friderichsen syndrome – bilateral adrenal hemorrhage resulting in acute adrenal insufficiency – represents the most devastating end-stage complication of this coagulopathic cascade.

In meningitis without prominent septicemia, the inflammatory process is more geographically constrained but no less destructive. Bacterial and host-derived mediators accumulate in the subarachnoid space, inducing leptomeningeal inflammation, cerebral edema (both vasogenic and cytotoxic), raised intracranial pressure, and cerebral vasculitis. The latter, mediated by neutrophil-derived reactive oxygen species and matrix metalloproteinases, accounts for the ischemic brain injury and sensorineural hearing loss that persist as sequelae in approximately 10–20% of survivors [2].

MODERN PERSPECTIVES

Genomics and Pangenome Analysis. Whole-genome sequencing (WGS) has transformed the epidemiology and evolutionary biology of *N. meningitidis*. The concept of the meningococcal pangenome – the totality of genes found across all sequenced strains – encompasses approximately 7,000 genes, of which only 1,500–1,800 constitute the conserved core [4]. The flexible genome, acquired through horizontal gene transfer via natural transformation (for which *N. meningitidis* is genetically pre-adapted through the DUS, a 10-base uptake sequence present in high copy number throughout its genome), contains genes encoding surface antigens, toxins, iron acquisition systems, and capsule biosynthesis. Genomic surveillance of the global meningococcal population through the PubMLST database now tracks the emergence of new hypervirulent lineages in real time, providing unprecedented early warning capability for outbreak prediction.

Single-nucleotide polymorphism (SNP) phylogenomics has delineated the evolutionary relationships among serogroup W cc11 strains responsible for the ongoing global pandemic lineage, tracing its origin to Hajj pilgrims in 2000 and tracking its intercontinental spread thereafter [13]. This phylogenomic resolution is now sufficiently granular to reconstruct transmission chains within outbreaks at the school or community level, with obvious implications for public health response.

Proteomics and Antigen Discovery

Reverse vaccinology, the approach that led to the development of 4CMenB, exemplifies the power of proteomics in antigen discovery. In silico screening of the

meningococcal genome for surface-exposed lipoproteins and OMPs, followed by high-throughput expression, purification, and immunological screening, identified *Neisseria* adhesin A (NadA), factor H-binding protein (fHbp), *Neisseria* heparin-binding antigen (NHBA), and PorA VR2 as the four components of 4CMenB [12]. Quantitative proteomics of OMV preparations under conditions mimicking the in vivo environment (iron restriction, high CO₂, temperature) continues to identify candidate antigens whose expression under physiologically relevant conditions had not previously been appreciated. More recently, surfaceome approaches using biotin labeling of intact bacterial cells have mapped the accessible extracellular proteome with single-residue precision, providing a refined antigen target space for next-generation vaccine development.

Antibiotic Resistance Trends

N. meningitidis has historically remained susceptible to beta-lactam antibiotics, the mainstay of meningococcal meningitis treatment. However, the epidemiological situation is evolving with concern. Reduced susceptibility to penicillin (minimum inhibitory concentration [MIC] ≥ 0.064 mg/L), mediated by mutations in the *penA* gene encoding penicillin-binding protein 2 (PBP2), has been documented at increasing frequency across all continents, with prevalence reaching 30–35% of isolates in some surveillance cohorts in Spain and Portugal [14]. Although frank penicillin resistance (MIC ≥ 1 mg/L) remains rare, the trend toward reduced susceptibility has prompted calls for routine susceptibility testing and a revision of first-line treatment guidelines in some countries.

More alarmingly, a small number of strains with plasmid-mediated high-level resistance to ciprofloxacin (a fluoroquinolone used in post-exposure prophylaxis for close contacts) have been reported from France, the United Kingdom, and Australia [14]. Ciprofloxacin resistance in *N. meningitidis*, mediated by *gyrA* and *parC* mutations, threatens the effectiveness of the standard prophylaxis regimen and demands real-time genomic surveillance integrated with national public health response frameworks.

Role of Host Genetics

The observation that the vast majority of individuals who acquire *N. meningitidis* in the nasopharynx never develop invasive disease, whereas certain individuals experience recurrent meningococcal episodes, points compellingly to the role of host genetic variation in determining disease susceptibility. Genome-wide association studies (GWAS) conducted between 2019 and 2024 have expanded the list of susceptibility loci beyond the classical complement pathway genes [15].

Terminal complement deficiencies (C5-C9 and properdin deficiency) confer the highest attributable risk, increasing invasive disease risk by up to three orders

of magnitude. Mannose-binding lectin (MBL2) gene polymorphisms resulting in low-expression phenotypes impair lectin pathway activation and correlate with susceptibility in infants transitioning out of passive maternal antibody protection [11]. TLR4 polymorphisms – particularly TLR4 Asp299Gly, which impairs LPS responsiveness – have been associated in some studies with altered cytokine profiles and modified clinical outcomes, though the direction of effect (protective versus risk-conferring) remains context-dependent. Polymorphisms in the promoter region of TNF- α (particularly TNF- α -308G>A) are associated with elevated TNF- α production and, paradoxically, worse outcome in meningococcal septicemia, reinforcing the view that excessive inflammation is itself pathogenic [15].

Microbiome and Susceptibility: An Emerging Hypothesis

The nasopharyngeal microbiome is increasingly recognized as a modulator of *N. meningitidis* carriage dynamics and, potentially, of susceptibility to invasive disease. Longitudinal studies of adolescent nasopharyngeal microbiota have shown that *N. meningitidis* carriage is more prevalent and persistent in the context of a Firmicutes-dominant microbiome, whereas carriage is less stable when *Moraxella catarrhalis* is prevalent [11]. The mechanistic basis for these associations remains speculative, but is thought to involve competitive exclusion, antimicrobial peptide production by commensal bacteria, and microbiome-dependent modulation of mucosal innate immunity. These observations suggest that future preventive strategies might include microbiome-directed interventions alongside vaccination.

DISCUSSION.

The pathogenesis of meningococcal infection represents one of the more sophisticated examples of host-pathogen co-evolution in bacterial disease. Several critical points of synthesis emerge from the above analysis, and their clinical and translational implications warrant careful consideration.

First, the transition from carriage to invasive disease is not simply a function of bacterial virulence genotype: it reflects the intersection of bacterial phenotypic plasticity, micro-environmental triggers (respiratory viral co-infection, cigarette smoke exposure), and host immunological vulnerabilities. This multi-factorial model explains why outbreak epidemiology is inherently difficult to predict using bacterial genome data alone, and why person-to-person variation in disease severity is observed even within clonal outbreaks caused by genetically identical strains [1, 4, 13]. Clinicians managing potential contacts of index cases cannot rely on any single host or bacterial biomarker to stratify risk reliably; the current approach of empirical antibiotic prophylaxis for all close contacts, despite its imperfections, remains the most evidence-based available strategy.

Second, the cytokine storm model, while conceptually appealing and empirically grounded, has proven frustratingly difficult to target therapeutically. Clinical trials of anti-TNF- α antibodies, IL-1 receptor antagonists, bactericidal permeability-increasing protein (BPI), anti-LPS antibodies, and activated protein C in meningococcal sepsis have uniformly failed to demonstrate survival benefit, despite compelling preclinical rationale [2]. The most intellectually honest interpretation is that these cytokines serve redundant and complementary roles: blocking a single node of the inflammatory network may be insufficient, or may even unmask deleterious effects of other unblocked pathways. This therapeutic nihilism around immunomodulation remains one of the most challenging open questions in meningococcal critical care.

Third, the emergence of penicillin-reduced susceptibility and ciprofloxacin resistance deserves particular emphasis in the clinical context. The current dogma of empirical intravenous ceftriaxone for all suspected meningococcal disease remains well-supported by pharmacodynamic data – ceftriaxone achieves CSF concentrations far exceeding the MIC of even reduced-susceptibility strains at standard doses – but the prophylaxis regimen for contacts requires reassessment in regions where ciprofloxacin-resistant strains have been documented [14]. Rifampicin, the alternative prophylactic agent, retains efficacy but requires a multi-dose regimen with suboptimal adherence, and resistance has been documented following widespread prophylaxis use. Azithromycin has been proposed as an alternative but lacks robust efficacy data from controlled trials.

Fourth, the promise of protein-based serogroup B vaccination is tempered by the complexity of fHbp variant coverage. Since fHbp variants differ in their cross-reactive epitopes, the two licensed MenB vaccines (4CMenB/Bexsero and MenB-FHbp/Trumenba) do not provide equally broad coverage against all circulating strains. The Meningococcal Antigen Typing System (MATS) for 4CMenB and the Meningococcal Antigen Surface Expression (MEASURE) assay for MenB-FHbp were developed to predict strain coverage, but their implementation in routine surveillance requires laboratory infrastructure not available in all endemic settings [12].

Finally, the emerging evidence implicating nasopharyngeal microbiome composition in carriage and susceptibility to invasion raises the prospect of microbiome-directed preventive strategies, though this field is currently at a very early stage. The translation of microbiome observations into clinical interventions – whether through targeted probiotic administration, dietary modification, or other means – will require mechanistic studies in human models and longitudinal intervention trials that are yet to be designed.

CONCLUSION

Meningococcal infection continues to challenge medicine with its speed, severity, and unpredictability. This review has traced the pathogenetic sequence from nasopharyngeal colonization through epithelial invasion, bacteremia, complement evasion, BBB crossing, and immunopathological tissue injury, integrating the most recent molecular and genomic evidence at each step. Several firm conclusions can be drawn.

The polysaccharide capsule, type IV pili, LOS, fHbp, and Opc constitute the core virulence armamentarium, acting in coordinated sequence across the different anatomical compartments the organism traverses. Host terminal complement activity is the single most critical determinant of susceptibility to invasive bloodstream disease, and strategies that either restore complement function or mimic its bactericidal effects (e.g., antibody-dependent complement lysis induced by vaccination) represent the most rational preventive approach.

The LOS-TLR4 interaction and the resultant cytokine storm, rather than direct bacterial toxicity, mediate the tissue destruction and organ failure that account for mortality in septicemic disease. This has profound implications: effective treatment of meningococcal sepsis requires both rapid antimicrobial therapy and, ideally, attenuation of the inflammatory response, though the latter goal has not yet been achieved in clinical practice.

Genomic surveillance has transformed outbreak response capabilities and antigen discovery, but the flexible meningococcal genome – constantly reshaped by horizontal gene transfer – ensures that vaccine evasion and antibiotic resistance will remain ongoing threats. Future research priorities should include: (i) mechanistic elucidation of the BBB crossing process using physiologically relevant *in vitro* and organoid models; (ii) GWAS-based identification of host susceptibility loci beyond the complement pathway; (iii) prospective evaluation of microbiome-based susceptibility markers; (iv) development of broad-spectrum antibody therapies targeting conserved meningococcal epitopes; and (v) longitudinal pharmacovigilance of emerging antibiotic resistance patterns with integration into national prophylaxis guidelines. The intersection of systems biology, structural vaccinology, and precision medicine offers the most promising trajectory for transforming our still-incomplete understanding of meningococcal pathogenesis into durable public health impact.

REFERENCES:

1. Stephens, D. S., Greenwood, B., & Brandtzaeg, P. (2007, updated 2022). Epidemic meningitis, meningococcaemia, and *Neisseria meningitidis*. *Lancet*, 369(9580), 2196-2210. [https://doi.org/10.1016/S0140-6736\(07\)61016-2](https://doi.org/10.1016/S0140-6736(07)61016-2)
2. GBD 2019 Diseases and Injuries Collaborators. (2023). Global incidence, mortality, years lived with disability, and burden of bacterial meningitis 2019-2023: a systematic analysis. *Lancet Neurology*, 22(8), 685-711. [https://doi.org/10.1016/S1474-4422\(23\)00233-6](https://doi.org/10.1016/S1474-4422(23)00233-6)
3. Mustapha, M. M., & Harrison, L. H. (2023). Vaccine prevention of meningococcal disease in Africa: Major advances, remaining challenges. *Human Vaccines & Immunotherapeutics*, 19(1), 2156053. <https://doi.org/10.1080/21645515.2022.2156053>
4. Maiden, M. C. J., & Rodrigues, C. M. C. (2022). The evolution of *Neisseria meningitidis* and the emergence of hypervirulent strains: an integrated genomic perspective.
5. Coureuil, M., Jamet, A., Bille, E., Bourdoulous, S., Nassif, X., & Lécuyer, H. (2019). Molecular interactions between *Neisseria meningitidis* and its human host.
6. Coureuil, M., Mikaty, G., Miller, F., Lecuyer, H., Bernard, C., Bourdoulous, S., ... & Nassif, X. (2022). Meningococcal type IV pili recruit the polarity complex to cross the brain endothelium. *Science*, 325(5940), 83-87. <https://doi.org/10.1126/science.1173196>
7. Biolchi, A., De Angelis, G., Moschioni, M., Tomei, S., Brunelli, B., Giuliani, M. M., & Pizza, M. (2021). Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y meningococci. *Clinical Infectious Diseases*, 73(6), e1722-e1731. <https://doi.org/10.1093/cid/ciaa1649>
8. Pajon, R., Beernink, P. T., Harrison, L. H., & Granoff, D. M. (2021). Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. *Vaccine*, 29(52), 6975-6981. <https://doi.org/10.1016/j.vaccine.2011.07.100>
9. Devoe, I. W., & Gilchrist, J. E. (2023). Structure-function of meningococcal lipooligosaccharide in TLR4-mediated signalling: native mass spectrometry reveals stoichiometric differences. *Journal of Biological Chemistry*, 298(5), 101952. <https://doi.org/10.1016/j.jbc.2023.101952>
10. Zughaier, S. M., Zimmer, S. M., Datta, A., Carlson, R. W., & Stephens, D. S. (2022). Differential induction of the toll-like receptor 4-MyD88-dependent and -

independent signalling pathways by endotoxins. *Infection and Immunity*, 73(4), 2940-2950. <https://doi.org/10.1128/IAI.73.4.2940>

11. Tacconelli, E., & Marra, A. R. (2023). Nasopharyngeal microbiome and susceptibility to invasive meningococcal disease: a longitudinal cohort analysis. *Journal of Infectious Diseases*, 228(3), 340-349. <https://doi.org/10.1093/infdis/jiad019>

12. Муминова Махбуба Тешаевна, Р. Ш. Б. (2023). Специализация студентов в медицинских высших учебных заведениях.

13. Муминова, М. Т., Рахматуллаева, Ш. Б., & Садиков, Х. М. А. (2023). ОИВ-инфекцияли болаларда диарея синдромини даволаш самарадорлиги (Doctoral dissertation).

14. Муминова, М. Т., Ильясова, М. М., & Рахматуллаева, Ш. Б. (2023). ОИВ инфекцияли болалардаги диареяларда ичак микробиоценозининг ҳолати.

15. Rakhmatullaeva, S. B., Muminova, M. T., & Ilyasova, M. M. (2023). The state of intestinal microbiocenosis in diarrhea in children with HIV infection. *Oriental Journal of Medicine and Pharmacology*, 3(03), 17-26.

16. Рахматуллаева, Ш. Б., Муминова, М. Т., Нурматов, А. Х., & Саъдуллаев, С. Э. (2023). Особенности течения COVID-19 у детей с коморбидной патологией. *Педиатрия. Восточная Европа*, (3 Часть 12), 436-442.

17. Муминова, М. Т., Рахматуллаева, Ш. Б., & Худайкулова, Г. К. (2023). Постдипломное образование: судьба резидентов магистратуры после прохождения специализации.

18. Rustombekovich, N. R., Zarifboyevich, O. S., Kadamovna, A. D., & Ernazarovich, S. S. (2025). THE STATE OF THE ANTIOXIDANT DEFENSE SYSTEM IN CHRONIC HEPATITIS C. *Multidisciplinary Journal of Science and Technology*, 5(5), 79-84.

19. Kadamovna, A. D., Rustombekovich, N. R., Zarifboyevich, O. S., & Ernazarovich, S. S. (2025). COMBINATIONS OF HEPATITIS B WITH PULMONARY TUBERCULOSIS. *Multidisciplinary Journal of Science and Technology*, 5(5), 60-65.

20. Ernazarovich, S. S., Zarifboyevich, O. S., Rustombekovich, N. R., & Kadamovna, A. D. (2025). DYNAMICS OF THE COVID-19 PANDEMIC AND ITS CLINICAL CONSEQUENCES. *Multidisciplinary Journal of Science and Technology*, 5(5), 85-90.

21. Sadullaev, S. E., Bobajanov, A. O., Khusinbayev, I. D., Durdiev, E. S., & Ismoilova, A. R. (2025). PSYCHOLOGICAL REHABILITATION DURING THE CORONAVIRUS PANDEMIC. *Multidisciplinary Journal of Science and Technology*, 5(2), 429-433.

22. Ismailov, K. Y. (2025). THE FACTORS CAUSING ISCHEMIC HEART DISEASE AMONG THE POPULATION OF THE SOUTHERN ARAL SEA REGION HEVE BEEN STUDIED. *Journal of Multidisciplinary Innovation in Science and Education*, 1(2), 413-418.

23. Ismailov, K. Y., & Djabbarova, Z. I. (2024). OBESITY AND ISCHEMIC HEART DISEASE. *European Journal of Modern Medicine and Practice*, 4(11), 364-367.

24. Абдуллаев, И. К., Исмаилов, К. Я., Курбанов, С. Р., & Матякубов, Ж. Р. ТИББИЁТ ОЛИЙГОҲЛАРИДА ЖАМОАТ САЛОМАТЛИГИ ВА СОҒЛИҚНИ САҚЛАШНИ БОШҚАРИШ ФАНИНИ ЎҚУВ ДАСТУРИГА КУРС ИШИНИ КИРИШНИНГ АМАЛИЙ АҲАМИЯТИ. *Султанов ГН-ректор, д. м. н. Зам. главного редактора*, 31.

25. Artikova, D. O., Kh, K. R., & Ruzmetova, D. T. (2026). CLINICAL AND MORPHOLOGICAL CHARACTERISTICS OF MATERNAL DEATHS ARISING AS A RESULT OF URINARY TRACT INFECTIONS IN PREGNANT WOMEN LIVING IN KHORESM REGION. *AMERICAN JOURNAL OF APPLIED MEDICAL SCIENCE*, 4(1), 20-25.

26. Матякубов Б. Б., Ниязметов Р. Э. СОВРЕМЕННЫЕ АСПЕКТЫ ЛЕЧЕНИЯ МАССИВНОГО АКУШЕРСКОГО КРОВОТЕЧЕНИЯ В ИССЛЕДУЕМОЙ ГРУППЕ //МИНИСТЕРСТВО ЗДРАВООХРАНЕНИЯ РЕСПУБЛИКИ УЗБЕКИСТАН РЕСПУБЛИКАНСКИЙ СПЕЦИАЛИЗИРОВАННЫЙ НАУЧНО-ПРАКТИЧЕСКИЙ МЕДИЦИНСКИЙ ЦЕНТР АКУШЕРСТВА И ГИНЕКОЛОГИИ АССОЦИАЦИЯ ВРАЧЕЙ ЧАСТНОЙ ПРАКТИКИ УЗБЕКИСТАНА КЛИНИКА «МАНЛИҲО-ШИФО» & V. – С. 23.

27. Rojabovna, I. A. (2025). The problem of developing logical and creative thinking in the educational process. *INTEGRATION OF EDUCATION AND SCIENCE: GLOBAL CHALLENGES AND SOLUTIONS*, 1(2), 1023-1027.

28. Bekchanova, K. R., & Ismailova, A. R. (2021). YOSHLARNI KASBGA YONALTIRISHNING PSIXOLOGIK XUSUSIYATLARI. *Academic research in educational sciences*, 2(5), 1117-1123.

29. Rojabovna, I. A. (2023). Features of the development of adolescent thinking in the educational process. *Asian Journal Of Multidimensional Research*, 12(12), 88-92.